Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?

Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States

(2015) Bruce K. Birmingham et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism

(2013) Y Tomita et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients

(2013) Hon-Kit Lee et al.   PHARMACOGENOMICS

Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

(2012) R Elsby et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers

(2011) Alicia J. Allred et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Systemic Exposure to Atorvastatin Between Asian and Caucasian Subjects

(2010) Kuan Gandelman et al.   AMERICAN JOURNAL OF THERAPEUTICS

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

(2009) J E Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia

(2008) Tsang-Bin Tzeng et al.   CURRENT MEDICAL RESEARCH AND OPINION

Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin

(2008) S. Kitamura et al.   DRUG METABOLISM AND DISPOSITION

Postmenopausal Hormone Therapy for Disease Prevention: Have We Learned Any Lessons from the Past?

(2007) J E Rossouw   CLINICAL PHARMACOLOGY & THERAPEUTICS